Longitudinal study of patients after surgical treatment for cervical lesions: detection of HPV DNA and prevalence of HPV-specific antibodies
Jazyk angličtina Země Německo Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- DNA virů analýza MeSH
- dospělí MeSH
- infekce onkogenními viry MeSH
- infekce papilomavirem epidemiologie imunologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- lidský papilomavirus 16 genetika imunologie izolace a purifikace MeSH
- longitudinální studie MeSH
- mladiství MeSH
- nádory děložního čípku chirurgie virologie MeSH
- následné studie MeSH
- nemoci cervix uteri chirurgie virologie MeSH
- Papillomaviridae genetika izolace a purifikace MeSH
- prevalence MeSH
- protilátky virové MeSH
- senioři MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- DNA virů MeSH
- protilátky virové MeSH
The principal aims of this study were to test whether persistence of human papillomavirus (HPV) DNA is predictive of recurrent disease in women after surgical treatment for cervical lesions, to distinguish between persistent and newly acquired HPV infection, and to observe the effect of surgical treatment on levels of HPV-specific antibodies. A group of 198 patients surgically treated for low-grade and high-grade squamous intraepithelial lesions and 35 age-matched controls were monitored for 18 months at 6-month intervals. The presence of HPV DNA in cervical smears was detected by means of consensus polymerase chain reaction, and serum levels of HPV-specific antibodies to HPV types 16, 18, 31, 33, and 45 were measured. In ten patients positive for HPV type 16 in consecutive samples, the HPV 16 variants were identified using a polymerase chain reaction specific for the long control region. Data regarding demographics, risk factors for cervical cancer, and risks related to HPV exposure were collected through a patient questionnaire. Subjects persistently positive for HPV DNA were more likely to present with cytological and/or colposcopical abnormalities. A higher reactivity to HPV-specific antibodies was observed in these women at the 18-month follow-up visit. All ten patients with HPV 16 infection detected in consecutive samples showed persistence of either the same prototype or the same variant during the follow-up period. Risky sexual behavior and smoking were more common in patients than in controls. Persistent HPV infection as demonstrated by both HPV DNA detection and antibody detection appears to be a risk factor for the recurrence of pathological findings in women after surgery. An individually based approach to surgical treatment is an important factor in the outcome of disease at follow-up.
Zobrazit více v PubMed
Gynecol Oncol. 2000 Nov;79(2):294-9 PubMed
J Virol. 1997 Mar;71(3):2463-72 PubMed
J Gen Virol. 1997 Sep;78 ( Pt 9):2199-208 PubMed
Virus Res. 2002 Nov;89(2):229-40 PubMed
J Natl Cancer Inst. 1995 Sep 20;87(18):1365-71 PubMed
Am J Obstet Gynecol. 2001 Apr;184(5):940-5 PubMed
Obstet Gynecol Surv. 2004 Jul;59(7):543-53 PubMed
Int J Cancer. 1994 Mar 15;56(6):802-6 PubMed
J Virol. 1993 Nov;67(11):6413-23 PubMed
Am J Obstet Gynecol. 2004 Apr;190(4):1046-51 PubMed
Eur J Clin Microbiol Infect Dis. 1999 Feb;18(2):126-32 PubMed
Eur J Gynaecol Oncol. 1992;13(6):507-13 PubMed
Am J Obstet Gynecol. 1996 Mar;174(3):937-42 PubMed
J Natl Cancer Inst. 1999 Jun 2;91(11):954-60 PubMed
J Pathol. 1999 Sep;189(1):12-9 PubMed
Gynecol Oncol. 1997 Jul;66(1):108-13 PubMed
Gynecol Oncol. 2003 Sep;90(3):587-92 PubMed
Lancet. 1993 Jun 19;341(8860):1594 PubMed
Int J Cancer. 2000 May 1;86(3):351-5 PubMed
Gynecol Oncol. 1999 Feb;72(2):199-201 PubMed
Int J Cancer. 1998 Aug 31;77(5):689-94 PubMed
J Natl Cancer Inst. 1994 Oct 19;86(20):1558-9 PubMed
Lancet. 2001 Nov 24;358(9295):1782-3 PubMed
J Med Virol. 2004 Sep;74(1):117-26 PubMed
J Natl Cancer Inst. 1997 Jun 4;89(11):796-802 PubMed
J Clin Microbiol. 2000 Sep;38(9):3388-93 PubMed
J Clin Microbiol. 1995 Nov;33(11):2957-62 PubMed
Gynecol Oncol. 1996 Apr;61(1):73-8 PubMed
JAMA. 1991 Jan 23-30;265(4):472-7 PubMed
Cancer Res. 1998 Feb 15;58(4):829-33 PubMed
J Infect Dis. 1993 Sep;168(3):610-7 PubMed
J Virol. 1995 Dec;69(12 ):7743-53 PubMed
Int J Cancer. 1996 Oct 21;69(5):364-8 PubMed
J Med Virol. 1999 Aug;58(4):378-86 PubMed
Oncology. 1998 Nov-Dec;55(6):517-20 PubMed
TTV and HPV co-infection in cervical smears of patients with cervical lesions
